{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:02:19Z","timestamp":1789642939758,"version":"4.0.0"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.semcancer.2022.03.028","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:36:08Z","timestamp":1648820168000},"page":"568-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"P2","title":["Chemokines driven ovarian cancer progression, metastasis and chemoresistance: Potential pharmacological targets for cancer therapy"],"prefix":"10.1016","volume":"86","author":[{"given":"Subhankar","family":"Bose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilash","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2022.03.028_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-1-60327-492-0_20","article-title":"Epidemiology of ovarian cancer","author":"Permuth-Wey","year":"2009","journal-title":"Cancer Epidemiol."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib2","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siege","year":"2014","journal-title":"Ca Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.semcancer.2022.03.028_bib3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.semcancer.2022.03.028_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"K\u00f6bel","year":"2008","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.semcancer.2022.03.028_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.21037\/tcr.2016.08.40","article-title":"TP53 mutations in epithelial ovarian cancer","volume":"5","author":"Zhang","year":"2016","journal-title":"Transl. Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2022.03.028_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399404007781","article-title":"Critical evaluation of p53 as a prognostic marker in ovarian cancer","volume":"6","author":"Hall","year":"2004","journal-title":"Expert Rev. Mol. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2022.03.028_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0952-7915(00)00201-6","article-title":"Chemokines in lymphopoiesis and lymphoid organ development","volume":"13","author":"Ansel","year":"2001","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0031-6997(24)01439-X","article-title":"International union of pharmacology. XXII. Nomenclature for chemokine receptors","volume":"52","author":"Murphy","year":"2000","journal-title":"Pharm. Rev."},{"issue":"2","key":"10.1016\/j.semcancer.2022.03.028_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1074-7613(00)80165-X","article-title":"Chemokines: a new classification system and their role in immunity","volume":"12","author":"Zlotnik","year":"2000","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.semcancer.2022.03.028_bib10","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1034\/j.1398-9995.2002.02166.x","article-title":"The chemokine system: tuning and shaping by regulation of receptor expression and coupling in polarized responses","volume":"57","author":"Locati","year":"2002","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.semcancer.2022.03.028_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nri3049","article-title":"Homeostatic chemokine receptors and organ-specific metastasis","volume":"11","author":"Zlotnik","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.semcancer.2022.03.028_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.molmed.2013.12.002","article-title":"Pathomechanisms: homeostatic chemokines in health, tissue regeneration, and progressive diseases","volume":"20","author":"Anders","year":"2014","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","article-title":"The chemokine superfamily revisited","volume":"36","author":"Zlotnik","year":"2012","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.semcancer.2022.03.028_bib14","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.1426","article-title":"Chemokines in tumor progression and metastasis","volume":"4","author":"Sarvaiya","year":"2013","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.dci.2003.09.006","article-title":"Chemokines","volume":"28","author":"Laing","year":"2004","journal-title":"Dev. Comp. Immunol."},{"key":"10.1016\/j.semcancer.2022.03.028_bib16","first-page":"1569","article-title":"Chemokines: key players in cancer progression and metastasis","volume":"3","author":"Singh","year":"2011","journal-title":"Front. Biosci. (Sch. Ed.)"},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2022.03.028_bib18","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3389\/fonc.2019.01115","article-title":"Insights into mechanisms of tumor and immune system interaction: association with wound healing","volume":"9","author":"Ponomarev","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.028_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy","author":"Yang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ijc.28335","article-title":"Mixed\u2010polarization phenotype of ascites\u2010associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse","volume":"134","author":"Reinartz","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2022.03.028_bib22","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1172\/JCI87252","article-title":"Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer","volume":"126","author":"Yin","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.semcancer.2022.03.028_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejca.2015.12.016","article-title":"Targeting the tumour microenvironment in ovarian cancer","volume":"56","author":"Hansen","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nri978","article-title":"Alternative activation of macrophages","volume":"3","author":"Gordon","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.semcancer.2022.03.028_bib25","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1007\/s13277-015-3133-8","article-title":"Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients","volume":"36","author":"Wertel","year":"2015","journal-title":"Tumor Biology."},{"issue":"9255","key":"10.1016\/j.semcancer.2022.03.028_bib26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"issue":"6776","key":"10.1016\/j.semcancer.2022.03.028_bib27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/35006097","article-title":"Control of TH 2 polarization by the chemokine monocyte chemoattractant protein-1","volume":"404","author":"Gu","year":"2000","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semcancer.2022.03.028_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000000672","article-title":"Combined immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancer","volume":"26","author":"B\u00f6sm\u00fcller","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.028_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.734188","article-title":"The recruitment of neutrophils to the tumor microenvironment is regulated by multiple mediators","volume":"12","author":"SenGupta","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2022.03.028_bib30","first-page":"223","article-title":"Macrophage inflammatory protein-1 alpha (MIP-1 alpha)\/CCL3: as a biomarker","author":"Bhavsar","year":"2015","journal-title":"Gen. Methods Biomark. Res. Appl."},{"issue":"12","key":"10.1016\/j.semcancer.2022.03.028_bib31","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/nm1201-1339","article-title":"Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells","volume":"7","author":"Zou","year":"2001","journal-title":"Nat. Med."},{"issue":"7353","key":"10.1016\/j.semcancer.2022.03.028_bib32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Network","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1074\/jbc.M209470200","article-title":"Structure-function relationship between the human chemokine receptor CXCR3 and its ligands","volume":"278","author":"Clark-Lewis","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.semcancer.2022.03.028_bib34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2174\/1381612826666200115095937","article-title":"Exploring dysregulated signaling pathways in cancer","volume":"26","author":"Nisar","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.semcancer.2022.03.028_bib35","first-page":"1","article-title":"Key chemokines direct migration of immune cells in solid tumors","author":"Kohli","year":"2021","journal-title":"Cancer Gene Ther."},{"issue":"7","key":"10.1016\/j.semcancer.2022.03.028_bib36","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.semcancer.2022.03.028_bib37","doi-asserted-by":"crossref","first-page":"9804","DOI":"10.3390\/ijms22189804","article-title":"Chemokine-directed tumor microenvironment modulation in cancer immunotherapy","volume":"22","author":"Bule","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.semcancer.2022.03.028_bib38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/wound.2012.0380","article-title":"Chemokines and their receptors are key players in the orchestra that regulates wound healing","volume":"2","author":"Martins-Green","year":"2013","journal-title":"Adv. Wound Care"},{"issue":"05","key":"10.1016\/j.semcancer.2022.03.028_bib39","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1160\/TH07-01-0040","article-title":"Chemokines as mediators of angiogenesis","volume":"97","author":"Mehrad","year":"2007","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.semcancer.2022.03.028_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10388-019-00706-8","article-title":"Chemokines and their receptors as biomarkers in esophageal cancer","volume":"17","author":"Goto","year":"2020","journal-title":"Esophagus"},{"issue":"6","key":"10.1016\/j.semcancer.2022.03.028_bib41","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.surg.2014.02.006","article-title":"Chemokines and chemokine receptors: update on utility and challenges for the clinician","volume":"155","author":"Roy","year":"2014","journal-title":"Surgery"},{"issue":"12","key":"10.1016\/j.semcancer.2022.03.028_bib42","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/1078-0432.CCR-14-2777","article-title":"The ovarian cancer chemokine landscape is conducive to homing of vaccine-primed and CD3\/CD28\u2013costimulated T cells prepared for adoptive therapy","volume":"21","author":"Zsiros","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib43","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1172\/JCI117933","article-title":"The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer","volume":"95","author":"Negus","year":"1995","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.semcancer.2022.03.028_bib44","first-page":"1108","article-title":"Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites","volume":"8","author":"Milliken","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.028_bib45","doi-asserted-by":"crossref","unstructured":"M. Nowak, M. Soja, E. G\u0142owacka, K. Szy\u0142\u0142o, M. Misiek, M. Klink, EP940 chemokine expression in patients with ovarian cancer or benign ovarian tumors, BMJ Spec. J., 2019.","DOI":"10.1136\/ijgc-2019-ESGO.986"},{"issue":"4","key":"10.1016\/j.semcancer.2022.03.028_bib46","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1359-6101(01)00016-8","article-title":"Interleukin-8 and human cancer biology","volume":"12","author":"Xie","year":"2001","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.semcancer.2022.03.028_bib47","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5301\/JBM.2011.8616","article-title":"Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses","volume":"26","author":"Wang","year":"2011","journal-title":"Int. J. Biol. Mark."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1189\/jlb.1204712","article-title":"Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes","volume":"78","author":"Schutyser","year":"2005","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.semcancer.2022.03.028_bib49","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/0008-5472.CAN-05-3694","article-title":"Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas","volume":"66","author":"Hendrix","year":"2006","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2022.03.028_bib50","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/onc.2009.470","article-title":"Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes","volume":"29","author":"Yamaguchi","year":"2010","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.semcancer.2022.03.028_bib51","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2022.03.028_bib52","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1084\/jem.187.12.2009","article-title":"Interferon\u2013inducible T cell alpha chemoattractant (I-TAC): a novel Non-ELR CXC Chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3","volume":"187","author":"Cole","year":"1998","journal-title":"J. Exp. Med."},{"issue":"37","key":"10.1016\/j.semcancer.2022.03.028_bib53","doi-asserted-by":"crossref","first-page":"22878","DOI":"10.1074\/jbc.271.37.22878","article-title":"Characterization of \u03b2-R1, a gene that is selectively induced by interferon \u03b2 (IFN-\u03b2) compared with IFN-\u03b1","volume":"271","author":"Rani","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2022.03.028_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.646252","article-title":"CXCL11 correlates with antitumor immunity and an improved prognosis in colon cancer","volume":"9","author":"Cao","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.semcancer.2022.03.028_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154809","article-title":"CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7","volume":"125","author":"Puchert","year":"2020","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.semcancer.2022.03.028_bib56","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ajpath.2019.12.004","article-title":"CXCL11-CXCR3 Axis mediates tumor lymphatic cross talk and inflammation-induced tumor, promoting pathways in head and neck cancers","volume":"190","author":"Kumaravel","year":"2020","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib57","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317706226","article-title":"CXCL11 mediates TWIST1-induced angiogenesis in epithelial ovarian cancer","volume":"39","author":"Koo","year":"2017","journal-title":"Tumor Biol."},{"issue":"10","key":"10.1016\/j.semcancer.2022.03.028_bib58","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1878-0261.12362","article-title":"Feedback control of the CXCR 7\/CXCL 11 chemokine axis by estrogen receptor \u03b1 in ovarian cancer","volume":"12","author":"Benhadjeba","year":"2018","journal-title":"Mol. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2022.03.028_bib59","first-page":"1238","article-title":"Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration","volume":"41","author":"Mlynska","year":"2019","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-02221-0","article-title":"cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment","volume":"41","author":"Mishra","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-019-0517-1","article-title":"Hypoxia-inducible factor-1\u03b1 induces CX3CR1 expression and promotes the epithelial to mesenchymal transition (EMT) in ovarian cancer cells","volume":"12","author":"Singh","year":"2019","journal-title":"J. Ovarian Res."},{"issue":"20","key":"10.1016\/j.semcancer.2022.03.028_bib62","first-page":"5930","article-title":"Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer","volume":"62","author":"Scotton","year":"2002","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.semcancer.2022.03.028_bib63","first-page":"5822","article-title":"Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells","volume":"59","author":"Xu","year":"1999","journal-title":"Cancer Res."},{"issue":"7355","key":"10.1016\/j.semcancer.2022.03.028_bib64","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T reg cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.semcancer.2022.03.028_bib65","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2174\/138161209788453239","article-title":"Towards understanding the role of cancer-associated inflammation in chemoresistance","volume":"15","author":"de Visser","year":"2009","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.semcancer.2022.03.028_bib66","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1586\/1744666X.2015.1012158","article-title":"Lipopolysaccharide challenge: immunological effects and safety in humans","volume":"11","author":"Zielen","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"9","key":"10.1016\/j.semcancer.2022.03.028_bib67","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1289\/ehp.0800439","article-title":"Endotoxin and cancer","volume":"117","author":"Lundin","year":"2009","journal-title":"Environ. Health Perspect."},{"issue":"3","key":"10.1016\/j.semcancer.2022.03.028_bib68","doi-asserted-by":"crossref","DOI":"10.4110\/in.2019.19.e22","article-title":"Potential roles of innate immune chemokine and cytokine network on lipopolysaccharide-based therapeutic approach in ovarian cancer","volume":"19","author":"Ignacio","year":"2019","journal-title":"Immune Netw."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib69","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4161\/cc.8.1.7533","article-title":"Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance","volume":"8","author":"Alvero","year":"2009","journal-title":"Cell Cycle"},{"issue":"49","key":"10.1016\/j.semcancer.2022.03.028_bib70","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1038\/onc.2009.289","article-title":"TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer","volume":"28","author":"Szajnik","year":"2009","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib71","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3892\/ijo.2016.3442","article-title":"Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K\/Akt signaling pathways","volume":"48","author":"Zhou","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib72","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1074\/jbc.M113.502641","article-title":"Proteasome inhibition increases recruitment of I\u03baB kinase \u03b2 (IKK\u03b2), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells","volume":"289","author":"Singha","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib73","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canlet.2015.07.045","article-title":"Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer","volume":"369","author":"Mishra","year":"2015","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib74","first-page":"1","article-title":"The role of microRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.semcancer.2022.03.028_bib75","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-12-0206","article-title":"MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer","volume":"2","author":"Mitra","year":"2012","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.semcancer.2022.03.028_bib76","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1089\/dna.2019.5312","article-title":"Long noncoding RNA SCAMP1 targets miR-137\/CXCL12 axis to boost cell invasion and angiogenesis in ovarian cancer","volume":"39","author":"Song","year":"2020","journal-title":"DNA Cell Biol."},{"issue":"11","key":"10.1016\/j.semcancer.2022.03.028_bib77","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s12094-015-1325-8","article-title":"miR-448 negatively regulates ovarian cancer cell growth and metastasis by targeting CXCL12","volume":"17","author":"Lv","year":"2015","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.028_bib78","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.biopha.2018.08.044","article-title":"MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2","volume":"107","author":"Duan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.semcancer.2022.03.028_bib79","doi-asserted-by":"crossref","unstructured":"F.A. Turut, H. Acidereli, O. Cevik, Suppression of microRNA-144 promotes CXCR4 and CXCL12 expression and downregulates apoptosis in ovarian cancer cells, bioRxiv, 2020.","DOI":"10.1101\/2020.04.17.042382"},{"key":"10.1016\/j.semcancer.2022.03.028_bib80","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.omtn.2020.03.013","article-title":"miR-548e sponged by ZFAS1 regulates metastasis and cisplatin resistance of OC by targeting CXCR4 and let-7a\/BCL-XL\/S signaling axis","volume":"20","author":"Zhang","year":"2020","journal-title":"Mol. Ther.-Nucleic Acids"},{"issue":"11","key":"10.1016\/j.semcancer.2022.03.028_bib81","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/mc.22419","article-title":"CCL18 from tumor\u2010cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway","volume":"55","author":"Wang","year":"2016","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-016-0542-2","article-title":"CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling","volume":"15","author":"Lane","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.028_bib83","doi-asserted-by":"crossref","unstructured":"L.-N. Gao, M. Hao, X.-H. Liu, L. Zhang, Y. Dong, Y.-F. Zhang, X.-C. He, CXCL14 facilitates the growth and metastasis of ovarian carcinoma cells via activation of the Wnt\/\u03b2-catenin signaling pathway, 2021.","DOI":"10.21203\/rs.3.rs-606940\/v1"},{"issue":"10","key":"10.1016\/j.semcancer.2022.03.028_bib84","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/stem.1194","article-title":"Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem\u2010like cells via NF\u2010\u03baB\u2010mediated MMP\u20109 upregulation","volume":"30","author":"Long","year":"2012","journal-title":"Stem Cells"},{"issue":"7","key":"10.1016\/j.semcancer.2022.03.028_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021546","article-title":"Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer","volume":"6","author":"Gaudin","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.semcancer.2022.03.028_bib86","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1677\/ERC-10-0107","article-title":"The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor","volume":"17","author":"Bolitho","year":"2010","journal-title":"Endocr.-Relat. Cancer"},{"issue":"15","key":"10.1016\/j.semcancer.2022.03.028_bib87","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-10-0483","article-title":"CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis","volume":"16","author":"Yang","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2022.03.028_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083789","article-title":"CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NF-\u03baB activation via EGFR-transactivated Akt signaling","volume":"8","author":"Dong","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.semcancer.2022.03.028_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051848","article-title":"Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice","volume":"7","author":"Shang","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib90","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.3390\/ijms22052634","article-title":"The CXCL2\/IL8\/CXCR2 pathway is relevant for brain tumor malignancy and endothelial cell function","volume":"22","author":"Urbantat","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.semcancer.2022.03.028_bib91","first-page":"6304","article-title":"Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells","volume":"62","author":"Kijima","year":"2002","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.semcancer.2022.03.028_bib92","doi-asserted-by":"crossref","first-page":"8420","DOI":"10.1158\/0008-5472.CAN-04-1343","article-title":"Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4","volume":"64","author":"Marchesi","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.028_bib93","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.2147\/OTT.S195661","article-title":"Impact of CXCR4 and CXCR7 knockout by CRISPR\/Cas9 on the function of triple-negative breast cancer cells","volume":"12","author":"Yang","year":"2019","journal-title":"OncoTarg. Ther."},{"issue":"10","key":"10.1016\/j.semcancer.2022.03.028_bib94","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/gt.2017.69","article-title":"Targeting the CXCR4\/CXCL12 axis in treating epithelial ovarian cancer","volume":"24","author":"Mao","year":"2017","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib95","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2006.02.036","article-title":"Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression","volume":"103","author":"Jiang","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2022.03.028_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092629","article-title":"The prognostic value of CXCR4 in ovarian cancer: a meta-analysis","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2022.03.028_bib97","doi-asserted-by":"crossref","unstructured":"A. Bagri, T. Gurney, X. He, Y.-R. Zou, D.R. Littman, M. Tessier-Lavigne, S.J. Pleasure, The chemokine SDF1 regulates migration of dentate granule cells, 2002.","DOI":"10.1242\/dev.129.18.4249"},{"issue":"7","key":"10.1016\/j.semcancer.2022.03.028_bib98","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/stemcells.2004-0342","article-title":"Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF\u20101\u2013CXCR4 axis","volume":"23","author":"Kucia","year":"2005","journal-title":"Stem Cells"},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib99","first-page":"1723","article-title":"Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of CC chemokines","volume":"150","author":"Negus","year":"1997","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.68.1.1","article-title":"CXC chemokines in angiogenesis","volume":"68","author":"Belperio","year":"2000","journal-title":"J. Leukoc. Biol."},{"issue":"6","key":"10.1016\/j.semcancer.2022.03.028_bib101","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ejca.2006.01.006","article-title":"Cancer CXC chemokine networks and tumour angiogenesis","volume":"42","author":"Strieter","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2022.03.028_bib102","first-page":"1141","article-title":"Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments","volume":"114","author":"Kryczek","year":"2009","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib103","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"11","key":"10.1016\/j.semcancer.2022.03.028_bib104","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00262-011-1104-5","article-title":"Dual biological effects of the cytokines interleukin-10 and interferon-\u03b3","volume":"60","author":"Wilke","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.semcancer.2022.03.028_bib105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.yexcr.2011.10.012","article-title":"Chemokines in tumor development and progression","volume":"318","author":"Mukaida","year":"2012","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.semcancer.2022.03.028_bib106","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jnci\/90.6.447","article-title":"Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice","volume":"90","author":"Yoneda","year":"1998","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.semcancer.2022.03.028_bib107","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.semcancer.2022.03.028_bib108","doi-asserted-by":"crossref","first-page":"615","DOI":"10.18632\/oncoscience.181","article-title":"Chemokines and cellular plasticity of ovarian cancer stem cells","volume":"2","author":"Zou","year":"2015","journal-title":"Oncoscience"},{"issue":"8","key":"10.1016\/j.semcancer.2022.03.028_bib109","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.18632\/oncotarget.3462","article-title":"CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition","volume":"6","author":"Long","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.semcancer.2022.03.028_bib110","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/dvdy.20345","article-title":"The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it","volume":"233","author":"Hay","year":"2005","journal-title":"Dev. Dyn.: Off. Publ. Am. Assoc. Anat."},{"issue":"2","key":"10.1016\/j.semcancer.2022.03.028_bib111","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1083\/jcb.200512110","article-title":"Transforming growth factor-\u03b2 employs HMGA2 to elicit epithelial\u2013mesenchymal transition","volume":"174","author":"Thuault","year":"2006","journal-title":"J. Cell Biol."},{"issue":"10","key":"10.1016\/j.semcancer.2022.03.028_bib112","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3390\/cells8101118","article-title":"The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges","volume":"8","author":"Loh","year":"2019","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.semcancer.2022.03.028_bib113","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrc822","article-title":"Epithelial\u2013mesenchymal transitions in tumour progression","volume":"2","author":"Thiery","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-03966-7","article-title":"Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation","volume":"9","author":"Taki","year":"2018","journal-title":"Nat. Commun."},{"issue":"32","key":"10.1016\/j.semcancer.2022.03.028_bib115","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2217\/fon-2020-0095","article-title":"Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12\/CXCR4 axis","volume":"16","author":"Zhang","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.semcancer.2022.03.028_bib116","doi-asserted-by":"crossref","unstructured":"S. Nie, Y. Wan, H. Wang, J. Liu, J. Yang, R. Sun, H. Meng, X. Ma, Y. Jiang, W. Cheng, CXCL2-mediated ATR\/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer, 2021.","DOI":"10.21203\/rs.3.rs-397447\/v1"},{"issue":"2","key":"10.1016\/j.semcancer.2022.03.028_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171044","article-title":"Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2022.03.028_bib118","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3389\/fimmu.2020.00901","article-title":"Role of CC chemokines subfamily in the platinum drugs resistance promotion in cancer","volume":"11","author":"Reyes","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.semcancer.2022.03.028_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2021.12274","article-title":"Chemokine CCL20 promotes the paclitaxel resistance of CD44+ CD117+ cells via the Notch1 signaling pathway in ovarian cancer","volume":"24","author":"Chen","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.semcancer.2022.03.028_bib120","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3892\/ijo.2013.1819","article-title":"Bioinformatic analysis of chemokine (CC motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer","volume":"42","author":"Yin","year":"2013","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2022.03.028_bib121","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1158\/1078-0432.CCR-08-2024","article-title":"Role of eotaxin-1 signaling in ovarian cancer","volume":"15","author":"Levina","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0787-z","article-title":"CCL2\/CCL5 secreted by the stroma induce IL-6\/PYK2 dependent chemoresistance in ovarian cancer","volume":"17","author":"Pasquier","year":"2018","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2022.03.028_bib123","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.molonc.2014.03.016","article-title":"Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers","volume":"8","author":"Moisan","year":"2014","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib124","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1247\/csf.18029","article-title":"CCL20 promotes ovarian cancer chemotherapy resistance by regulating ABCB1 expression","volume":"44","author":"Su","year":"2019","journal-title":"Cell Struct. Funct."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1757-2215-3-15","article-title":"CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion","volume":"3","author":"Johnson","year":"2010","journal-title":"J. Ovarian Res."},{"issue":"4","key":"10.1016\/j.semcancer.2022.03.028_bib126","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/imt.11.20","article-title":"Immunity and immune suppression in human ovarian cancer","volume":"3","author":"Preston","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.semcancer.2022.03.028_bib127","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fimmu.2019.00333","article-title":"Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy","volume":"10","author":"Vilgelm","year":"2019","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.semcancer.2022.03.028_bib128","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.semcancer.2022.03.028_bib129","first-page":"4791","article-title":"CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes","volume":"30","author":"Fader","year":"2010","journal-title":"Anticancer Res."},{"issue":"2010","key":"10.1016\/j.semcancer.2022.03.028_bib130","article-title":"Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target","author":"Barbieri","year":"2010","journal-title":"J. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib131","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/75022","article-title":"Active movement of T cells away from a chemokine","volume":"6","author":"Poznansky","year":"2000","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.semcancer.2022.03.028_bib132","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/1535-7163.MCT-08-0966","article-title":"An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells","volume":"8","author":"Kwong","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"22","key":"10.1016\/j.semcancer.2022.03.028_bib133","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.1021\/jm300682j","article-title":"Chemokine receptor antagonists","volume":"55","author":"Pease","year":"2012","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.semcancer.2022.03.028_bib134","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-10-3143","article-title":"CXCL12\/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer","volume":"71","author":"Righi","year":"2011","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.semcancer.2022.03.028_bib135","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.4049\/jimmunol.1400201","article-title":"CXCL12\/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells","volume":"193","author":"Gil","year":"2014","journal-title":"J. Immunol."},{"issue":"2009","key":"10.1016\/j.semcancer.2022.03.028_bib136","article-title":"Modulation of CXCR4, CXCL12, and tumor cell invasion potential in vitro by phytochemicals","author":"Hsu","year":"2009","journal-title":"J. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib137","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1007\/s13277-014-1607-8","article-title":"Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells","volume":"35","author":"Yu","year":"2014","journal-title":"Tumor Biol."},{"issue":"14","key":"10.1016\/j.semcancer.2022.03.028_bib138","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1158\/0008-5472.CAN-09-4341","article-title":"Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy","volume":"70","author":"Agarwal","year":"2010","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.semcancer.2022.03.028_bib139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139237","article-title":"CXCR2 inhibition combined with sorafenib improved antitumor and antiangiogenic response in preclinical models of ovarian cancer","volume":"10","author":"Devapatla","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-020-00697-6","article-title":"Tumor-suppressor miRNA-27b-5p regulates the growth and metastatic behaviors of ovarian carcinoma cells by targeting CXCL1","volume":"13","author":"Liu","year":"2020","journal-title":"J. Ovarian Res."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-03348-z","article-title":"miR200-regulated CXCL12\u03b2 promotes fibroblast heterogeneity and immunosuppression in ovarian cancers","volume":"9","author":"Givel","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms3427","article-title":"Tumour angiogenesis regulation by the miR-200 family","volume":"4","author":"Pecot","year":"2013","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.semcancer.2022.03.028_bib143","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3892\/etm.2017.4118","article-title":"miR-9 functions as a tumor inhibitor of cell proliferation in epithelial ovarian cancer through targeting the SDF-1\/CXCR4 pathway","volume":"13","author":"He","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.semcancer.2022.03.028_bib144","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2017.03.094","article-title":"CCR2 blockade alters the tumor microenvironment immune infiltrate and enhances anti-tumor activity in ovarian cancer","volume":"145","author":"Binder","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2022.03.028_bib145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jnci\/djn024","article-title":"Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth","volume":"100","author":"Merritt","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"35","key":"10.1016\/j.semcancer.2022.03.028_bib146","doi-asserted-by":"crossref","first-page":"59123","DOI":"10.18632\/oncotarget.19289","article-title":"Mifepristone inhibits ovarian cancer metastasis by intervening in SDF-1\/CXCR4 chemokine axis","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2022.03.028_bib147","doi-asserted-by":"crossref","unstructured":"S. Hotte, H. Hirte, A. Iacobucci, D. Wong, L. Cantin, W. Korz, W. Miller, Phase I\/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in: Patients with Advanced Solid Cancers, AACR, 2007.","DOI":"10.1016\/S1359-6349(08)72339-5"},{"issue":"4","key":"10.1016\/j.semcancer.2022.03.028_bib148","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00280-013-2099-8","article-title":"A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors","volume":"71","author":"Sandhu","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0706-x","article-title":"Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors","volume":"7","author":"Bilusic","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2022.03.028_bib150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11523-014-0320-2","article-title":"Carlumab, an anti-CC chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study","volume":"10","author":"Brana","year":"2015","journal-title":"Target. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.028_bib151","doi-asserted-by":"crossref","unstructured":"D. Biasci, M. Smoragiewicz, C.M. Connell, Z. Wang, Y. Gao, J.E. Thaventhiran, B. Basu, L. Magiera, T.I. Johnson, L. Bax, CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response, Proc. Natl. Acad. Sci. USA, vol. 117(46), 2020, pp. 28960\u201370.","DOI":"10.1073\/pnas.2013644117"},{"key":"10.1016\/j.semcancer.2022.03.028_bib152","doi-asserted-by":"crossref","unstructured":"M.H. O\u2032Hara, W. Messersmith, H. Kindler, W. Zhang, C. Pitou, A.M. Szpurka, D. Wang, S.-B. Peng, B. Vangerow, A.A. Khan, Safety and pharmacokinetics of CXCR4 peptide antagonist, LY2510924, in combination with durvalumab in advanced refractory solid tumors, J. Pancreat. Cancer, 2020.","DOI":"10.1089\/pancan.2019.0018"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X22000840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X22000840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:20:29Z","timestamp":1760919629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X22000840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":152,"alternative-id":["S1044579X22000840"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.028","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemokines driven ovarian cancer progression, metastasis and chemoresistance: Potential pharmacological targets for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}